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Methods
Sample Collection: First Trimester placental tissue
Placental tissue was collected from electively terminated gravidities with informed consent of
healthy patients (with GA 5 – 11 weeks). Exclusion criteria were a maternal age under 18,
maternal BMI >25, maternal pathologies (self-reported). Ethical approval was obtained from
the Medical University of Graz Ethics Committee (31-019 ex 18/19; 26-132 ex 13/14).
Sample Collection: Term Control Tissue
Term samples were collected in  the University Hospital  of  the RWTH Aachen,  Germany.
Sampling was approved by the local ethical committee (EK 148/07) and informed consent
was obtained from each participating woman. Immediately after delivery, a random tissue
sample (1x1x1cm) of the medial third of the placenta was cut from vital cotyledons that were
macroscopically free of infarct areas or other obvious pathologies. Amnion and decidua were
dissected and remaining tissue were rinsed twice in NaCl 0.9% 4°C to remove blood and
then snap frozen in liquid nitrogen and stored at -80°C until processing.
Sample Collection: Serum collection from patients undergoing assisted reproductive
technology (ART)
This  prospective  observational  study  was  performed  at  a  single  academic  tertiary
hospital  (Department  of  Obstetrics  and  Gynecology,  Medical  University  of  Graz,  Austria)
between September 2019 and January 2020. The study was approved by the institutional
review board (Ethics committee at the Medical University of Graz, Austria; 30-514 ex 17/18).
Patients were invited to participate if  they were 18 years or older and presented with an
indication  for  in  vitro  fertilization.  Eligible  patients  were  approached  by  members  of  the
research team when they  arrived  at  the  outpatient  clinic.  Written  informed consent  was
obtained from all participants.
Sample Collection: Preeclamptic placentae from Graz
Study samples were recruited retrospectively immediately after delivery at the inpatient clinic
of the Department of Obstetrics and Gynecology, University Hospital Graz, Austria between
2018 and 2019. Preeclampsia was defined according to the ISSHP guidelines (Brown MA,
Pregnancy Hypertension, 2018). 27 patients (41%) received prophylactic low dose aspirin, as
a result of the first trimester preeclampsia screening test or because of risk factors such as
history of preeclampsia in a previous pregnancy. Low dose aspirin was started before the 16th
week  gestational  age,  as  recommended.  The  study  was  approved  by  the  local  Ethics
committee at the Medical University of Graz (26-132 ex 13/14) and informed consent was
obtained from each participating woman.
Sample Collection: Preeclamptic placentae from Oslo
Pregnant  women were recruited prior  to elective caesarian section after  informed written
consent, as previously described1,  from women with either preeclamptic (or normotensive
pregnancies. Preeclampsia was defined as new onset hypertension (blood pressure ≥140/90
mmHg) and new onset proteinuria (≥1+ on dipstick, or ≥30 protein/creatinine ratio) at ≥20
weeks gestation. Early-onset preeclampsia was defined as delivery prior to gestational week
34. Placental villous tissue biopsies were cut from the center of central normal appearing
cotyledons, and were snap frozen in liquid nitrogen and stored at −80°C until use.  The study
was approved by the Regional committee for Medical and Health Research Ethics in South-
Eastern Norway, and performed according to the Helsinki Declaration. 
Sample Collection: Early gestation low and high-risk population
Determination of uterine artery resistance indices (RI) was performed in women attending a
clinic  for  termination  of  pregnancy  in  the  first  trimester,  as  previously  described2 at  St.
George's Hospital (London, UK). Ethical committee approval and full written consent were
obtained (reference, 01.96.8 and 01.78.5). Inclusion criteria were singleton pregnancy, GA of
9 to 14 weeks by crown-rump length (assigned by transvaginal measurement in accordance
with local unit clinical policy), normal fetal anatomy, and nuchal translucency with no known
maternal medical condition or history of recurrent miscarriage. High-resistance cases were
defined as a mean RI >95th percentile with bilateral  diastolic notches.  Normal-resistance
cases had a mean RI of <95th percentile. Previous studies have determined that cases with
UtAD RI >95th percentile in  the first  trimester had a 5-fold higher risk of  developing PE
compared  to  cases  with  UtAD  RI  <95th  percentile3.  Tissue  obtained  from  first-trimester
surgical terminations of pregnancy was collected and rinsed in ice-cold phosphate-buffered
saline. Placental villous tissue was separated from the decidua by blunt dissection and was
randomly sampled and divided. Approximately 100 mg of tissue was snap frozen in liquid
nitrogen in two to three aliquots and stored at −70°C until use. 
Cell Culture
For  treatments,  culture  medium  was  supplemented  with  Angiotensin  II  at  a  working
concentration of 0.1 µM. Candesartan was used at 0.1 µM, while DMSO at the same volume
served as solvent control. Cells or placental explants were treated with 0.1µM AngII (Sigma-
Aldrich,  Merck,  Vienna,  Austria) for  indicated  timepoints.  Recombinant  human  Leptin
(Gibco® Life Technologies) was added to the medium with a concentration of 100 ng/ml.
AngIV (Sigma-Aldrich, Merck,  Vienna, Austria) was used at 4 nmol working concentrations
for the timepoints indicated.
Viability Assay
To  test  for  possible  cytotoxicity  of  the  compounds  used  for  treatment,  the  lactate
dehydrogenase (LDH) release was analyzed. Culture medium supernatants of the cells were
centrifuged  at  2000rpm for  5min  and  LDH release  determined  with  an  LDH cytotoxicity
detection  kit  (TaKaRa  Clontech)  according  to  the  manufacturer’s  protocol,  measured  at
490nm with SparkTM 10M (Tecan). Positive high controls were cells treated with Triton X-100
(molecular SIGMA biology, cell culture medium background and low untreated controls were
used to test for cytotoxicity of each of the compounds’ highest concentration and longest time
point as used in cell culture protocols. 
RNA isolation and RT-qPCR
Placental  tissue  was  homogenised  in  RNA Lysis  Buffer  (AllPrep  DNA/RNA/Protein  Mini,
Qiagen, Austin, Texas) using an UltraTurrax (IKA) and cells were lysed in RNA Lysis Buffer
(peqlab,  VWR  International,  Avantor,  Darmstadt,  Germany)  using  cellscraper.  RNA was
isolated according to the manufacturer’s instructions (peqlab,  VWR International,  Avantor,
Darmstadt, Germany or AllPrep DNA/RNA/Protein Mini, Qiagen, Austin, Texas). RNA quality
was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA).  Quality check was followed by reverse transcription of  1µg total  RNA per reaction
using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA,
USA),  according to the manufacturer’s  manual.  qPCR was performed with Blue S’Green
qPCR Kit (Biozym, CityVienna, Austria) using a Bio-Rad CFX96 cycler and specific primers
for RAS components, and fetal sex determination, (see below in Table S1). Ct values and
relative quantification of gene expression were automatically generated by the CFX Manager
3.1  Software  (Bio-Rad  Laboratories;  Hercules,  CA,  USA)  using  the  expression  of  first
trimester placenta specific reference genes TBP, HPRT1, 18s as a reference chosen by their
calculated M-Value.
In situ mRNA detection based on padlock probe technology
In situ padlock probe procedures were performed as described previously  4.  In short,  the
target-mRNA is reverse transcribed and linear oligonucleotides (ie padlock probes) bind with
their  5´-  and  3´parts  to  the  complementary  cDNA sequencing  forming  a  circular  DNA
structure. After ligation, this circular DNA structure is amplified forming micron sized DNA
structures which can be targeted by fluorescent probes5. For oligonucleotide sequences see
Table S2.
Protein isolation and immunoblotting
Placental tissue was homogenized in Lysis Buffer (AllPrep DNA/RNA/Protein Mini, Qiagen,
Austin,  Texas)  using  an  UltraTurrax  (IKA)  and  protein  was  isolated  according  to  the
manufacturer’s instructions (AllPrep DNA/RNA/Protein Mini, Qiagen, Austin, Texas).  
Cells were washed with PBS and lysed in RIPA buffer (Sigma-Aldrich, Saint Louis, MO, USA)
including protease inhibitor cocktail (Roche Diagnostics; Mannheim, Germany). Cell lysates
were centrifuged at 8000×g and 4 °C for 10 min. The concentration of total tissue protein was
determined in clear supernatants according to the Lowry method. Additionally,  30 µg total
protein  were  applied  to  precast  10% Bis-Tris  gels  (NuPAGE,  Novex,  Life  Technologies).
Blotting  on  a  0.45  µm  nitrocellulose  membrane  (Hybond,  Amersham  Biosciences,  GE
Healthcare Life Sciences, Little Chalfont, UK) was followed by analysis of blotting efficiency
by Ponceau staining (Ponceau S solution, Sigma Aldrich). Membranes were cut in horizontal
strips at molecular weight ranges for target proteins. Various primary antibodies for target
proteins  were  used  at  tested  concentrations  (see  Table  S3)  and  as  reference  for
normalization  monoclonal  anti-beta  actin  antibody  (12.4  ng/mL,  clone  AC-15,  abcam,
Cambridge, UK) were applied to membrane strips overnight at 4 °C. HRP conjugated rabbit
anti-goat (1:3000, Dako) and anti-mouse IgG (1:3000, Bio-Rad), respectively, were used as
secondary antibodies  and incubated on membranes for  2h at  RT.  Immunodetection  was
performed with a chemiluminescent immunodetection kit (Western Bright chemiluminescence
Substrate Quantus, Biozym, Austria) according to the manufacturer´s instructions. Images
were acquired with FluorChem Q System (Alpha Innotech, Cell Bioscienes, Santa Clara, CA,
USA). Band densitometry was performed using Image Studio quantification software (Image
Studio™ Lite Software version, Li-Cor Biosciences, Germany).
Immunofluorescence Staining
Formalin fixed and paraffin embedded (FFPE) first trimester and term placenta sections were
deparaffinized  and  subsequently  labelled  with  primary  antibodies  (see  Table  S3)  and
secondary  goat  anti-mouse  or  anti-rabbit  Alexa  Fluor  555/633/488  (1:200,  Invitrogen,
Carlsbad;  CA,  USA)  for  30  min  each.  After  three  washing  steps  in  PBS and  a  10-min
blocking step with  irrelevant  mouse IgG1 (10 μg/ml,  DakoCytomation)  the  sections  were
labelled with FITC conjugated anti-keratin antibody (Dako, Denmark). Nuclei are stained with
DAPI by mounting sections with Vectashield (Vector Laoratories, Burlingame, CA, USA).
FACS Analysis
BeWo cell experiments were analysed with the BD FACSCanto II flow cytometer and BD
FACSDiva software (BD Bioscience). Data analysis was performed with FlowJo v.10 (FlowJo
LLC).
Serum Angiotensin Measurement
Serum conditioning for equilibrium analysis was performed at 37 °C followed by stabilization
through the addition of an enzyme inhibitor cocktail (Attoquant Diagnostics, Vienna, Austria)
as described previously6.  The samples then underwent C-18-based solid-phase-extraction
and  were  subjected  to  LC-MS/MS  analysis  using  a  reversed-phase  analytical  column
operating in line with a Xevo TQ-S triple quadruple mass spectrometer (Waters). Previous
results  have  shown  similar  qualitative  outcomes  when  comparing  the  quantification  of
circulating  (stabilized  immediately  at  blood  drawing)  and  equilibrium  angiotensin  peptide
levels6.  Stabilized  equilibrated  serum  samples  were  further  spiked  with  stable  isotope
labelled internal standards for each angiotensin metabolite at a concentration of 200 pg/ml.
Internal  standards  were  used  to  correct  for  peptide  and  steroid  recovery  of  the  sample
preparation procedure for  each analyte in each individual sample. Analyte concentrations
were reported in  pM and are  calculated considering the corresponding response factors
determined in appropriate calibration curves, on condition that integrated signals exceeded a
signal-to-noise ratio of 10.
Overrepresentation Analysis
Differentially expressed genes were examined with the  functional enrichment analysis web
tool WebGestalt (WEB-based Gene SeT AnaLysis Toolkit)7,8.
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Supplemental Tables and Figures












































AAG CTG GAA CGG GTG ATC
CTA
CCA GAG AGA ACA TAA GCT
CCC C
RNPEP
AGT ACA ACG GGG TGA TAG
AAG A
AGA CAA GGG TTC TCC ATT
CCT
Table S2. Primer sequences of Padlock Probe Detection Sequence
Reverse transcription primer
























































Lin33 Cy3 - CCTCAATGCACATGTTTGGCTCC
/5Phos/ indicates phosphorylation on the 5’-end of the padlock probes; Hybridization
arms which are complement to the target cDNA sequence are underlined; reporter
sequences for the detection probe is highlighted in red and the 5’-end of the detection
probe is Cy3 labeled
 













CD31 Ab18364 rabbit Abcam










Table S4. Overrepresentation Analysis of Array Data
Gene Set Description Size Expect Ratio P-value
GO:0001659 temperature homeostasis 7 1.1235 3.5604 0.011182 
GO:0007565 female pregnancy 7 1.1235 3.5604 0.011182 
GO:0009653 anatomical structure morphogenesis 45 7.2222 1.5231 0.019988 
GO:0032386 regulation of intracellular transport 8 1.2840 3.1154 0.020234 
GO:0044706 multi-multicellular organism process 8 1.2840 3.1154 0.020234 
GO:0106106 cold-induced thermogenesis 5 0.80247 3.7385 0.027376 
GO:0120161
regulation  of  cold-induced
thermogenesis 
5 0.80247 3.7385 0.027376 
GO:1990845 adaptive thermogenesis 5 0.80247 3.7385 0.027376 
GO:0033157
regulation  of  intracellular  protein
transport 
5 0.80247 3.7385 0.027376 
GO:0046822
regulation  of  nucleocytoplasmic
transport 
5 0.80247 3.7385 0.027376 
Table S5. Baseline characteristics of control population
Two independent study populations are shown. First trimester placental tissue was collected
from electively terminated gravidities with informed consent of healthy patients (with GA 5 –
11 weeks). Exclusion criteria were a maternal age under 18, maternal BMI >25, maternal
pathologies (self-reported).  Term samples were collected in the University Hospital  of  the
RWTH  Aachen,  Germany.  Sampling  was  approved  by  the  local  ethical  committee  (EK
148/07) and informed consent was obtained from each participating woman. Values are the






Fetal sex (f) % 58.5 44.1
sex (m) % 41.5 55.9
CRL cm 1.90 (4.5)
weight g 2513 (987)
percentile % 45.1 (21.48)
gestational age d 54 (11.8) 245 (33.6)
Maternal age years 26.45 (6.15) 31.79 (5.43)
prepregnancy BMI kg/m2 - 23.87 (4.87)
gestational weight kg 59.17 (12.04) 77.62 (14.66)
BMI kg/m2 21.83 (2.86) 28.14 (5.21)
prepregnancy smoking % - 75
non-smoking % - 25
In pregnancy smoking % 47.1 11.8
non-smoking % 52.5 88.2
Placental volume cm3 1.72 (1.47)
Birth Mode SVD % - 20.6
prim CS % - 41.2
sec CS % - 36.8
VE % - 1.5
Table S6. Baseline characteristics of ART patients
Gestational age d 48.4 (3.5)
Height m 163.3 (4.8)
Weight kg 58.9 (15.6)
BMI kg/m2 22.0 (4.9)
Smoking n 2
Non-Smoking n 8
n=10, values shown as mean (SD)
Table S7. Baseline characteristics of PE study population Graz
Patients were treated with aspirin or not (low dose aspirin daily starting from before the 16 th
gestational  week);  in  a linear regression model significant  predictors of  placental  LNPEP
mRNA expression were aspirin treatment and fetal  sex, whereby aspirin intake in control
groups predicted higher LNPEP levels compared to PE or control without low dose aspirin
groups,  and  females  had  lower  LNPEP  mRNA  expression  (p<.05).
PE-preeclamsia; eoPE: early-onset PE (delivery <34 gestational weeks); loPE: late-onset PE
(delivery ≥34 gestational weeks). Values shown as mean (SD).
  ctrl PE eoPE loPE
n 15 27 12 15
Low dose 
aspirin
 + [n(%)] 6 (40) 9 (55.6) 7 (58.3) 5 (53.3)
 - [n(%)] 9 (60) 15 (33.3) 4 (33.3) 8 (33.3)
Birth Mode Prim. CS [n(%)] 8 (53.3) 23 (85.2) 11 (91.7) 12 (80)
 Sec. CS [n(%)] 3 (20) 2 (7.4) 1 (8.3) 1 (6.7)
 SVD [n(%)] 3 (20) 2 (7.4) 0 (0) 2 (13.3)
 VE [n(%)] 1 (6.7) 0 (0) 0 (0) 0(0)
Fetal Sex male [n(%)] 11 (73.3) 13 (48.1) 8 (66.7) 5 (33.3)




































25.91 (4.7)25.93 (5.8)24.75 (4.5)26.94 (6.8)
 weight 
prepregnancy
[kg (mean(SD)] 69.7 (14.2)71.7 (18.7)69.4 (16.5)73.6 (20.7)
 weight at delivery [kg (mean(SD)] 83.5 (16.5)85.9 (21.2)82.1 (15.8)88.32 
(24.3)
Table S8. Baseline characteristics of PE study population Oslo
PE-preeclamsia; eoPE: early-onset PE (delivery <34 gestational weeks); loPE: late-onset PE
(delivery ≥34 gestational weeks). Values shown as mean (SD).
  ctrl PE eoPE loPE
n 14 27 13 14
Fetal Sex male [n(%)] 8 (57.1) 6 (46.2) 8(57.1)





































































Table S9.  Baseline characteristics of study population with uterine artery resistance
index (lower-risk vs. higher-risk)
lower risk higher risk
n 8 9
maternal age years 25 (6.50) 29 (7.43)
mean RI 0.74 (0.11) 0.88 (0.03)
GA days 73.3 (5.6) 72.9 (3.6)
Values are shown in mean (SD).
Figure S1. Extended RAS
Extended  RAS  with  multiple  angiotensin  conversion  products  (Ang  =  Angiotensin)  and
conversion enzymes (ACE and ACE2: angiotensin conversion enzyme; REN: renin; ANPEP:
alanyl aminopeptidase; ENPEP: glutamyl aminopeptidase; RNPEP: arginyl aminopeptidase;
DPP3:  dipeptidyl  peptidase  3;  arrows  show  conversion)  and  receptors  (AGTR1/2:
angiotensin II receptor type 1 or 2; MAS1: MAS1 proto-oncogene G-protein coupled receptor;
LNPEP: leucyl and cystinyl  aminopeptidase = angiotensin IV receptor = placental leucine
aminopeptidase; arrows with circular ends show ligand acting on receptor);
AngIII is a substrate for LNPEP and is degraded to AngIV (arrow not shown).
Figure S2. scRNA-seq data from first trimester placental tissues
UMAP and tSNE embeddings of scRNAseq data is shown with the cell type annotations used
in expression heatmaps. Data for first  trimester placenta was obtained from Vento-Tormo
et.al,  2018  9;  VCT:  villous  cytotrophoblast;  SCT:  syncytiotrophoblast;  EVT:  extravillous
trophoblast; HB: Hofbauer cells; dM1 – dM3: decidual macrophages; fFB1-2: fetal fibroblast;
Figure S3. Extended RAS in scRNA-seq data from term and preterm samples
Placental extended RAS expression in control term samples.  (A) Single cell RNA seq data
from 25 scRNA-seq libraries published by Pique-Regi et al., 2019 who are kindly providing
their data via http://placenta.grid.wayne.edu/ Pique-Regi et al., annotation used for samples
obtained  from  chorioamniotic  membrane  (CAM),  placental  villi  (PV),  basal  plate  (BP).
Extended RAS expression with (B) angiotensinogen AGT (C) angiotensin II receptor type 1
AGTR1  (D) leucyl  and  cystinyl  aminopeptidase  LNPEP  and  conversion  enzymes  (E)
angiotensin conversion enzyme ACE  (F) ACE2  (G) ENPEP: glutamyl aminopeptidase  (H)
ANPEP:  alanyl  aminopeptidase;  (I)  DPP3:  dipeptidyl  peptidase  (J) RNPEP:  arginyl
aminopeptidase; not shown REN, MAS and AGTR2 (no placental expression or not found in
data set)
Figure S4. RAS-associated components in scRNA-seq data
Figure from placental scRNA-seq data from Vento-Tormo et al, Nature 2018. Left-hand side:
No RNA expression can be found on the maternal site for following genes and very low
expression  in  foetal  fibroblasts:  OXTR =  oxytocin  receptor,  OXT oxytocin,  APLN apelin,
APLNR  apelin  receptor,  BDKRB1/2  bradykinin  receptor  B1  and  B2,  AVPR1A-1B-2
vasopressin receptor 1A – 1B – 2, AVP vasopressin. Cell types: VCT villous cytotrophoblast,
SCT  syncytiotrophoblast,  EVT  extravillous  trophoblast,  HB  Hofbauer  cells,  dM3
Macrophages, fFB1/2 foetal fibroblasts. – On the right-hand side: see MAS1 as receptor to
Ang1-7 lacking expression in placental villi.
Figure S5. In situ padlock probe mRNA detection and quantitative image analysis.
(A) CHO cells not expressing AGTR1 as negative control for AGTR1 padlock probes and (B)
showing AGTR1 overexpressing CHO cells (CHO-AT1R) as positive control, with yellow dots
representing  rolling  circle  amplification  products  of  AGTR1 padlock  probes  with  a  Cy3
backbone (C) AGTR1 expression in CHO and CHO-AT1R cells as validated by qPCR (norm.
to  GAPDH) (D)  full  four  channel  image  showing  AGTR1 transcripts  (arrows) (E)  Single
channel for autofluorescence correction, marking padlock probes signals in pink (F) Channel
with CD34 staining, note the automatic vessel recognition based on fluorescence intensity
thresholds (G)  Full  4-channel  immunofluorescence  slidescan  used  to  detect  AGTR1
transcripts  (H)  Vessels  (light  blue)  against  distance  mappings;  cell  nuclei  in  green  (I)
Combined  image  of  vessel  areas,  nuclei  and  immunofluorescence  image  (J)  Part  of
slidescan used to calculate  ACTB transcripts to vessel distance based on the automated
analysis software settings. 
Figure S6. Placental extended RAS expression 
(A) First trimester placental RAS mRNA expression compared to positive controls:  MAS1:
Brain,  AGTR1:  Kidney,  AGTR2:  Lung;  LNPEP:  Brain (B-E)  Expression  of  REN,  ACE2,
ENPEP, DPP3  across gestation in healthy male (m) and female (f) control placentae (line
represents  linear  regression  and  95%  confidence  bands;  n=252);  Extended  RAS  with
multiple  angiotensin  conversion  enzymes  (REN:  renin;  ACE2:  angiotensin  conversion
enzyme 2; ENPEP: glutamyl aminopeptidase; DPP3: dipeptidyl peptidase. 
Figure  S7.  Placental  LNPEP is  not  altered  in  preterm  labour  compared  to  term
deliveries.
(A) Sampling and scRNA-sequencing chorioamniotic membranes (CAM), basal plate (BP) or
placental villi (PV) from term no labor (TNL), term in labor (TIL) and preterm labor (PTL) was
examined; Data is from 25 scRNA-seq libraries published by Pique-Regi et al., 2019 who are
kindly  providing  their  data  via  http://placenta.grid.wayne.edu/  (B)  LNPEP expression  in
chorioamniotic membranes (CAM), basal plate (BP) or placental villi (PV) across all cell types
was unchanged between term no labor (TNL), term in labor (TIL) and preterm labor (PTL) (C)
Overlapping expression levels of LNPEP in major cell types (see A for cell type description,
plots show UMAP projection of scRNA-seq data). 
Figure  S8.  Gating  strategy  for  normalizing  Seahorse  XF  metabolic  assays  to  cell
number.
Cells  were  stained  with  Hoechst  and  only  positive  cells  were  sorted.  BeWo cells  from
experiments were analyzed with the BD FACSCanto II flow cytometer and BD FACSDiva
software (BD Bioscience). Data analysis was performed with FlowJo v.10 (FlowJo LLC).
Figure S9. Baselined data from Seahorse XF metabolic assays.
The data shows the significantly elevated max. OCR after BAM15 administration in (A) AngII
and  (B) AngIV pretreated samples to compensate the initially lower  baseline OCR (n=3;
sig<0.05).
Figure S10. Protein-protein interaction networks and overrepresentation analysis.
(A) Protein-protein interaction network; the nodes represent the significantly regulated genes
from the array (p>0.05, regulation >1.5fold). Nodes colored in red are annotated to UniProt-
Keyword „Secreted“ (KW-0964). Edge thickness shows increasing confidence levels (>0.15;
PPI  enrichment  p=0.0023).  (B) Over-Representation  Analysis  of  significantly  regulated
genes, top GO terms include adaptive thermogenesis, female pregnancy and regulation of
nucleocytoplasmic transport (enrichment categories Biological Process, p<0.059
